Moderna has reportedly started early-stage work on a hantavirus vaccine, with the effort conducted in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Korea University’s Vaccine Innovation Center. The report comes as investors reacted quickly to the prospect of a new program in a market that has historically rewarded credible platform expansion into infectious diseases. While Moderna has not disclosed clinical timelines, the report underscores how quickly “earliest-stage” vaccine news can move biotech expectations, particularly for pathogens with no approved vaccine. Hantaviruses can cause severe disease including hantavirus cardiopulmonary syndrome in the Americas. The development also lands amid heightened public attention following a WHO-tracked cruise-ship cluster linked to hantavirus cases and deaths, adding visibility to the gap in prevention options.